Zoetis Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Zoetis Inc. (ZTS) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 0.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-02-12
- Zoetis Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was 0.60%, a 14.29% decline from fiscal 2023.
- Zoetis Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 0.70%, a 0.00% change from fiscal 2022.
- Zoetis Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 0.70%, a 16.67% increase from fiscal 2021.
- Zoetis Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 0.60%, a 14.29% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.60% 10-K · filed 2026-02-12 | |
| 2023-12-31 | 0.70% 10-K · filed 2026-02-12 | |
| 2022-12-31 | 0.70% 10-K · filed 2025-02-13 | |
| 2021-12-31 | 0.60% 10-K · filed 2024-02-13 | |
| 2020-12-31 | 0.70% 10-K · filed 2023-02-14 | |
| 2019-12-31 | 0.70% 10-K · filed 2022-02-15 | |
| 2018-12-31 | 0.50% 10-K · filed 2021-02-16 | |
| 2017-12-31 | 1.30% 10-K · filed 2020-02-13 | |
| 2016-12-31 | 1.40% 10-K · filed 2019-02-14 | |
| 2015-12-31 | 2.80% 10-K · filed 2018-02-15 | -2.80% 10-K · filed 2016-02-24 |
| 2014-12-31 | 1.50% 10-K · filed 2017-02-16 | -1.50% 10-K · filed 2015-02-27 |
| 2013-12-31 | -1.20% 10-K · filed 2016-02-24 | |
| 2012-12-31 | -0.30% 10-K · filed 2015-02-27 | |
| 2011-12-31 | -2.30% 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |